Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
1. FDA approved Novo Nordisk's Alhemo for hemophilia patients aged 12 and older. 2. Alhemo offers subcutaneous treatment, improving convenience over IV infusions. 3. The pivotal study showed significant reductions in bleeding episodes for patients. 4. NVO stock rose 1.91% to $47.97 following the approval. 5. Alhemo competes with existing therapies by targeting TFPI for clotting improvement.